Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 2 of 18
Next
>>
>
26 to 50 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-20	Everolimus	3	72	flat	flat	BT20 everolimus 0 3 72	8	2.422	Inf	0.475	0.456	0.0	0.475	0.01	0.602	0.0632	0.543	Inf	0.478	0.534	0.0	0.478	0.01	0.561	0.0844	0.534
BT-20	AS605240	3	72	sigmoid	sigmoid	BT20 AS-605240 0 3 72	8	2.607	Inf	0.845	0.0823	4.13	0.662	0.292	0.729	0.0199	NA	Inf	0.81	0.897	3.97	0.589	0.284	0.712	0.0239	NA
BT-20	ZSTK474	3	72	sigmoid	sigmoid	BT20 ZSTK474 0 3 72	8	2.609	0.457	-0.00222	0.296	0.783	-0.31	0.895	0.982	5.76e-06	NA	0.422	0.163	0.702	0.422	0.0	0.82	0.971	2.52e-05	NA
BT-20	Pictilisib	3	72	sigmoid	sigmoid	BT20 pictilisib 0 3 72	8	2.566	0.839	0.172	0.22	0.914	-0.0483	1.09	0.954	9.59e-05	NA	0.843	0.254	0.768	0.809	0.0179	0.898	0.918	0.000551	NA
BT-20	Buparlisib	3	72	sigmoid	sigmoid	BT20 buparlisib 0 3 72	8	2.529	0.629	-0.303	0.26	1.06	-0.565	1.46	0.994	2.13e-07	NA	0.603	0.0696	0.764	0.603	0.0	1.52	0.984	4.36e-06	NA
BT-20	Sirolimus	3	72	flat	flat	BT20 rapamycin 0 3 72	8	2.661	Inf	0.54	0.46	0.0	0.54	0.01	NA	NA	0.54	Inf	0.499	0.499	0.0	0.499	0.01	NA	NA	0.499
BT-20	GDC-0980	3	72	sigmoid	sigmoid	BT20 apitolisib 0 3 72	8	2.502	0.0976	-0.115	0.437	0.107	-0.0716	1.53	0.994	2.41e-07	NA	0.0894	0.13	0.62	0.0732	0.163	1.96	0.996	6.83e-08	NA
BT-549	AZD-6482	3	72	sigmoid	sigmoid	BT549 AZD6482 0 3 72	8	1.744	8.87	0.616	0.0979	2.2	0.324	0.749	0.993	2.93e-07	NA	115.0	0.69	0.918	1.91	0.476	0.744	0.993	4.19e-07	NA
BT-549	AZD8055	3	72	sigmoid	sigmoid	BT549 AZD8055 0 3 72	8	1.757	0.0178	0.159	0.59	0.0122	0.145	0.913	0.942	0.000193	NA	0.0479	0.383	0.555	0.00973	0.372	0.854	0.954	9.74e-05	NA
BT-20	Omipalisib	3	72	sigmoid	sigmoid	BT20 omipalisib 0 3 72	8	2.586	0.00689	-0.587	0.893	0.044	-0.714	0.478	0.958	7.32e-05	NA	0.00572	0.017	0.281	0.00491	0.0669	0.945	0.983	4.7e-06	NA
BT-20	BX-912	3	72	flat	flat	BT20 BX-912 0 3 72	8	2.619	Inf	0.904	0.0795	0.0	0.904	0.01	0.000173	0.999	0.918	Inf	0.879	0.9	0.0	0.879	0.01	0.00619	0.982	0.896
BT-20	AZD8055	3	72	sigmoid	sigmoid	BT20 AZD8055 0 3 72	8	2.694	0.0351	0.345	0.472	0.0116	0.313	0.89	0.934	0.000286	NA	0.0291	0.343	0.506	0.00813	0.306	0.743	0.922	0.000471	NA
BT-20	KIN001-244	3	72	flat	flat	BT20 KIN001-244 0 3 72	8	2.608	Inf	0.841	0.062	0.0	0.841	0.01	0.489	0.133	0.935	Inf	0.805	0.922	0.0	0.805	0.01	0.475	0.145	0.919
BT-20	Trametinib	3	72	sigmoid	sigmoid	BT20 trametinib 0 3 72	8	2.539	Inf	0.64	0.208	0.104	0.541	0.392	0.967	3.69e-05	NA	Inf	0.604	0.761	0.0656	0.513	0.391	0.964	4.56e-05	NA
BT-549	Everolimus	3	72	sigmoid	flat	BT549 everolimus 0 3 72	8	1.587	59.5	0.533	0.425	1e-05	0.395	0.1	0.702	0.0264	NA	Inf	0.656	0.685	0.0	0.656	0.01	0.48	0.141	0.685
BT-20	MK2206	3	72	sigmoid	sigmoid	BT20 MK-2206 0 3 72	8	2.449	1.73	0.252	0.12	3.23	-0.504	1.11	0.988	1.77e-06	NA	1.69	0.318	0.877	1.69	0.0	1.18	0.979	9.03e-06	NA
BT-20	Alpelisib	3	72	sigmoid	sigmoid	BT20 alpelisib 0 3 72	8	2.541	1.21	0.199	0.21	5.83	-1.0	0.697	0.881	0.00167	NA	1.12	0.272	0.775	1.12	0.0	0.764	0.791	0.00916	NA
BT-549	GDC-0980	3	72	sigmoid	sigmoid	BT549 apitolisib 0 3 72	8	1.802	0.162	0.0283	0.377	0.158	0.0179	1.2	0.994	2.53e-07	NA	0.268	0.302	0.709	0.128	0.294	1.2	0.992	4.85e-07	NA
BT-20	PI103	3	72	sigmoid	sigmoid	BT20 PI-103 0 3 72	8	2.496	0.373	0.0139	0.282	0.387	-0.0286	1.52	0.994	1.99e-07	NA	0.359	0.183	0.735	0.279	0.162	1.56	0.988	1.71e-06	NA
BT-20	Torin2	3	72	sigmoid	sigmoid	BT20 Torin2 0 3 72	8	2.458	0.019	-0.64	0.751	0.234	-1.0	0.438	0.959	6.92e-05	NA	0.0147	0.0148	0.379	0.0123	0.0598	0.727	0.977	1.28e-05	NA
BT-549	KIN001-244	3	72	sigmoid	sigmoid	BT549 KIN001-244 0 3 72	8	1.740	Inf	0.861	0.0287	4.69	0.681	0.74	0.922	0.00047	NA	Inf	0.882	0.975	4.7	0.729	0.732	0.919	0.000531	NA
BT-20	PIK-93	3	72	sigmoid	sigmoid	BT20 PIK-93 0 3 72	8	2.532	2.65	0.419	0.097	7.54	-1.0	1.05	0.982	5.47e-06	NA	2.5	0.42	0.892	2.5	0.0	1.17	0.971	2.45e-05	NA
BT-20	CAL-101	3	72	flat	flat	BT20 idelalisib 0 3 72	8	2.589	Inf	0.916	0.0535	0.0	0.916	0.01	0.0547	0.845	0.944	Inf	0.894	0.932	0.0	0.894	0.01	0.0506	0.856	0.929
HCC38	AZD-6482	3	72	sigmoid	sigmoid	HCC38 AZD6482 0 3 72	8	1.420	Inf	0.821	0.0615	0.324	0.826	5.0	0.849	0.00342	NA	Inf	0.875	0.957	0.323	0.879	5.0	0.846	0.00367	NA
HCC38	AS605240	3	72	flat	flat	HCC38 AS-605240 0 3 72	8	1.343	Inf	0.958	-0.0162	0.0	0.958	0.01	-0.233	1.0	1.01	Inf	0.972	1.01	0.0	0.972	0.01	-0.235	1.0	1.01

|<
<<
Previous
Page 2 of 18
Next
>>
>
26 to 50 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)